Search 

• 3-step procedure
• Instant results
• Whole blood, serum or plasma specimens
• Up to 24 month shelf-life at 2 – 30° C
• Compact, single-use, 1.28 oz. package
• No refrigeration required
• Built-in procedural and reagent control line
• Standardized procedure across all products

http://www.linkedin.com/pub/hayden-y-t-huang/22/227/913

Memorial Sloan Kettering Cancer Center — the world’s oldest and largest private cancer center — has devoted more than 130 years to exceptional patient care, innovative research, and outstanding educational programs. Today, we are one of 45 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment.

The close collaboration between our physicians and scientists is one of our unique strengths, enabling us to provide patients with the best care available as we work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan Kettering has an impact on cancer treatment and biomedical research around the world.

Learn more about Memorial Sloan Kettering.

Mercadyne Advisors LLC advises private and public companies regarding capital strategy, business strategy, board governance, and restructuring. 

Mercadyne enables public companies to maximize shareholder value by positioning the company’s capitalization, Board and enterprise such that Wall Street will reward them for their business. 

Mercadyne also provides private companies seeking capital and liquidity an alternative financing path to the conventional, strict venture capital-to-large IPO process. We provide these emerging growth companies with an alternative public offering (APO) or direct public offering (DPO), structure via a public vehicle or small IPO (SIPO) strategy.

 Led >10 biologics PKPD mathematical modeling and data analysis projects in oncology, diabetes, inflammation and Alzheimer's disease.

- Conceived the idea for a novel technology in the area of antibody drug conjugates to specifically target the tumor cells. Gathered a team of 5 to implement the technology. Got buy-in from senior management. Based on this technology, an antibody drug is being developed in Pfizer (patent in preparation).

- Co-invented a technology to improve the dosing of antibody drugs (patent application filed). A drug based on this technology is in the pipeline.

Specialties: - Feasibility analysis: Assessment of new biotherapeutic drugs, modalities and technologies
- Mechanism based translation: Preclinical to phase 1 clinical trials
- Biotherapeutics PKPD
- Monoclonal antibody drug property and dose selection
- Use of predictive mathematical modeling to design bio-better therapeutics
- Business development: Due diligence for licensing opportunities